69 results about "MS multiple sclerosis" patented technology

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of patients with MG or MS.

The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods include subcutaneous administration of anti-CD20 antibodies and provide efficacy and safety at extended subcutaneous dosing intervals.

Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day.

The invention discloses a tomography and targeted energy thermal therapy system and method based on an acousto-optic coupling functional film layer, and relates to the technical field of noninvasive medical diagnosis and treatment. The system comprises an intelligent processing carrier, an acousto-optic coupling function film layer, a scanning mechanism, an energy treatment module and a processing and temperature control module. The intelligent processing carrier at least comprises a 20Hz-20kHz audio unit, a pickup unit, an optical signal unit and a processor; the acousto-optic coupling functional film layer is of a single physical structure and is inseparable, acoustic frequency conversion focusing imaging and targeted warm delivery at 42-47 DEG C are achieved in the same physical area in a time-sharing mode, the acoustic processing layer achieves 1000-8000 frequency doubling through a multi-stage resonance microcavity array, and the echo signal-to-noise ratio is larger than or equal to 15 dB; the scanning mechanism comprises a plurality of modes such as rotation, translation, multi-device array, human body movement, local limb movement, human body bearing support device movement and the like; the energy forms cover all types of light, electromagnetism, radio frequency and the like capable of generating a warm effect, including but not limited to non-contact or contact energy delivery modes. The traditional Chinese medicine composition is suitable for tumors, infections, inflammations, and all lesions sensitive to temperature of 42-47 DEG C including nervous system lesions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis and the like, is low in cost, free of radiation and easy to popularize, and has extremely high creativity and practical value.

The present disclosure provides, in one aspect, compounds, compositions, and methods for reducing and / or inhibiting the activity of p38gamma. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for promoting remyelination. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for treating, preventing, and / or ameliorating one or more diseases or disorders in a subject, including but not limited to multiple sclerosis (MS), inflammatory disease, and cancer.

The present disclosure provides methods of treating multiple sclerosis (MS) using Compound 1 represented by the following structure, or a pharmaceutically acceptable salt thereof, in combination with dihydroxymethyl fumarate (DRF).

The disclosure relates to the treatment, diagnosis and / or prevention of multiple sclerosis (MS) by using an immunodominant protein or peptide. More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.

The present disclosure relates to therapeutic regimens for treating multiple sclerosis (MS). These methods utilize the administration to a patient of Ofalimumab as an anti-CD20 monoclonal antibody during a load dose regimen and maintenance regimen.

The present disclosure relates to therapeutic regimens for treating multiple sclerosis (MS). These methods utilize the administration to a patient of Ofalimumab as an anti-CD20 monoclonal antibody during a load dose regimen and maintenance regimen.

The present disclosure provides methods of treating multiple sclerosis (MS) using Compound 1 represented by the following structure or a pharmaceutically acceptable salt thereof.

A DMA replication-associated protein (Rep) for multiple sclerosis (MS) is described, wherein (a) an increased amount of Rep protein or fragments thereof in a sample from a subject compared to an amount in a control sample or an increased amount of anti-Rep protein antibodies to antigen in a sample from a subject compared to an amount in a control sample is associated with a diagnosis of MS, wherein the Rep protein is an MSBI1 Rep or MSBI2 Rep.

The present disclosure relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based compounds. More particularly, the present disclosure provides a class of compounds that can inhibit and / or attenuate apoptosis via caspase 3 for the treatment of various degenerative disorders. Additionally, the present disclosure relates to methods for treating specific degenerative disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, spinal cord injury, complication due to diabetes, multiple sclerosis (MS), muscular dystrophy (MD), Parkinson's disease (PD), irritable bowel syndrome (IBS) and Alzheimer's disease (AD) in a patient comprising administering to the patient an effective amount of a present compound.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of MS in a subject. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that are characteristic of the status of MS. In some embodiments, differential modifications and / or differential accessibility are detected and quantified, at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with MS. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating MS.

To provide methods for treating multiple sclerosis (MS) in a patient.SOLUTION: Provided is a method comprising administering to a patient an effective amount of an anti-CD20 antibody, the method comprising a first exposure and second, third, and / or fourth additional exposures.SELECTED DRAWING: Figure 7

Some methods of analyzing one or more brain lesions of a patient comprise, for each of the lesion(s), calculating one or more lesion characteristics from a first 3-dimensional (3D) representation of the lesion obtained from data taken at a first time and a second 3D representation of the lesion obtained from data taken at a second time that is after the first time. The characteristic(s) can include a change, form the first time to the second time, in the lesion's volume and / or surface area, the lesion's displacement from the first time to the second time, and / or the lesion's theoretical radius ratio at each of the first and second times. Some methods comprise characterizing whether the patient has multiple sclerosis and / or the progression of multiple sclerosis in the patient based at least in part on the calculation of the lesion characteristic(s) of each of the lesion(s).

Provided are methods and kits for early determination of disease outcome and prognosis of Multiple Sclerosis (MS) patients and for adjustment of suitable treatment.

The disclosure relates to the treatment, diagnosis and / or prevention of multiple sclerosis (MS) by using an immunodominant protein or peptide. More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.

Provided are methods for assessing T cell receptor b chain complementary determining region 3 (TCRb CDR3) sequences. In certain embodiments, prior to the assessing, the subject has been identified as having, or is suspected of having, multiple sclerosis (MS). According to some embodiments, at the time of the assessing, the subject has one or more non-specific symptoms consistent with MS. Also provided are methods comprising administering an MS therapy to a subject identified as comprising T cells that express a T cell receptor b chain (TCRb) comprising a TCRb CDR3 sequence set forth in the present disclosure. Computer readable media and systems for assessing TCRb CDR3 sequences are also provided.

The application discloses a cerebrospinal fluid low-abundance protein biomarker for multiple sclerosis diagnosis and application thereof, and belongs to the field of biomedical technology. The application obtains the MS cerebrospinal fluid biomarker with high specificity and sensitivity through high-throughput proteomics technology screening and strict clinical verification, and establishes a standardized detection method, thereby providing a new core biomarker PFKP protein for the diagnosis of MS, enriching the technical means for early diagnosis of MS, and having good market application prospect and social and economic benefits.

The present invention relates to the management of conditions other than multiple sclerosis in treatment of patients with Ofalimumab, and specifically provides methods of multiple sclerosis (MS) treatment that allow for the control of conditions other than MS, such as infections.

To provide a method for treating relapsing multiple sclerosis.SOLUTION: (R) - l - (l-acryloylpiperidin-3-yl) - 4-amino-3 - (4-phenoxyphenyl) - 1H - imidazo [4, 5-c] pyridin-2 (3H) - one to a subject in need thereof. Another aspect of the present disclosure is to provide methods of treating RMS comprising administering to a subject in need thereof BTK inhibitors, including (R) - l - (l-acryloylpiperidin-3-yl) - 4-amino-3 - (4-phenoxyphenyl) - imidazo [4, 5-c] pyridin-2 (LA) - one.SELECTED DRAWING: Figure 1

The present invention provides compositions and methods of using them for treating or ameliorating multiple sclerosis (MS) by administering a formulation comprising 40 mg of glatiramer acetate intramuscularly to the MS patient.

The present invention relates to biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and even more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).

The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.

The present disclosure relates to treatment regimens for the treatment of multiple sclerosis (MS). These methods include subcutaneous administration of anti-CD20 antibodies and provide efficacy and safety with extended subcutaneous administration intervals.

The present disclosure is directed to isolated cell populations comprising stable regulatory T cells and methods of producing the same.

The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.

This application relates to the field of medicinal chemistry, specifically disclosing a piperidine derivative and its pharmaceutical composition, uses, and preparation method. The piperidine derivative has the following general formula: [Formula omitted]. This piperidine derivative can be effectively used to treat or prevent multiple sclerosis, exhibiting unexpected synergistic effects in animal models: it not only significantly improves neurological function impairment and promotes recovery, but also simultaneously and profoundly reduces the levels of key pro-inflammatory cytokines IFN-γ and IL-17. This invention provides a novel small molecule drug candidate for the treatment of multiple sclerosis that combines central penetration, neuroprotection, and comprehensive immunomodulation.